First Time Loading...

Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 40.47 USD -1.41% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

MRUS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. [ Read More ]

The intrinsic value of one MRUS stock under the Base Case scenario is 35.95 USD. Compared to the current market price of 40.47 USD, Merus NV is Overvalued by 11%.

Key Points:
MRUS Intrinsic Value
Base Case
35.95 USD
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Merus NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MRUS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Merus NV

Provide an overview of the primary business activities
of Merus NV.

What unique competitive advantages
does Merus NV hold over its rivals?

What risks and challenges
does Merus NV face in the near future?

Has there been any significant insider trading activity
in Merus NV recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Merus NV.

Provide P/S
for Merus NV.

Provide P/E
for Merus NV.

Provide P/OCF
for Merus NV.

Provide P/FCFE
for Merus NV.

Provide P/B
for Merus NV.

Provide EV/S
for Merus NV.

Provide EV/GP
for Merus NV.

Provide EV/EBITDA
for Merus NV.

Provide EV/EBIT
for Merus NV.

Provide EV/OCF
for Merus NV.

Provide EV/FCFF
for Merus NV.

Provide EV/IC
for Merus NV.

Show me price targets
for Merus NV made by professional analysts.

What are the Revenue projections
for Merus NV?

How accurate were the past Revenue estimates
for Merus NV?

What are the Net Income projections
for Merus NV?

How accurate were the past Net Income estimates
for Merus NV?

What are the EPS projections
for Merus NV?

How accurate were the past EPS estimates
for Merus NV?

What are the EBIT projections
for Merus NV?

How accurate were the past EBIT estimates
for Merus NV?

Compare the revenue forecasts
for Merus NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Merus NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Merus NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Merus NV compared to its peers.

Compare the P/E ratios
of Merus NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Merus NV with its peers.

Analyze the financial leverage
of Merus NV compared to its main competitors.

Show all profitability ratios
for Merus NV.

Provide ROE
for Merus NV.

Provide ROA
for Merus NV.

Provide ROIC
for Merus NV.

Provide ROCE
for Merus NV.

Provide Gross Margin
for Merus NV.

Provide Operating Margin
for Merus NV.

Provide Net Margin
for Merus NV.

Provide FCF Margin
for Merus NV.

Show all solvency ratios
for Merus NV.

Provide D/E Ratio
for Merus NV.

Provide D/A Ratio
for Merus NV.

Provide Interest Coverage Ratio
for Merus NV.

Provide Altman Z-Score Ratio
for Merus NV.

Provide Quick Ratio
for Merus NV.

Provide Current Ratio
for Merus NV.

Provide Cash Ratio
for Merus NV.

What is the historical Revenue growth
over the last 5 years for Merus NV?

What is the historical Net Income growth
over the last 5 years for Merus NV?

What is the current Free Cash Flow
of Merus NV?

Financials

Balance Sheet Decomposition
Merus NV

Current Assets 368.8m
Cash & Short-Term Investments 354.4m
Receivables 4m
Other Current Assets 10.5m
Non-Current Assets 86.7m
Long-Term Investments 57.3m
PP&E 23.5m
Intangibles 1.8m
Other Non-Current Assets 4.1m
Current Liabilities 69.1m
Accounts Payable 4.6m
Accrued Liabilities 40.2m
Other Current Liabilities 24.3m
Non-Current Liabilities 30.1m
Other Non-Current Liabilities 30.1m
Efficiency

Earnings Waterfall
Merus NV

Revenue
43.9m USD
Operating Expenses
-200.5m USD
Operating Income
-156.5m USD
Other Expenses
1.6m USD
Net Income
-154.9m USD

Free Cash Flow Analysis
Merus NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MRUS Profitability Score
Profitability Due Diligence

Merus NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
25/100
Profitability
Score

Merus NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

MRUS Solvency Score
Solvency Due Diligence

Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRUS Price Targets Summary
Merus NV

Wall Street analysts forecast MRUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRUS is 62.05 USD with a low forecast of 52.52 USD and a high forecast of 72.45 USD.

Lowest
Price Target
52.52 USD
30% Upside
Average
Price Target
62.05 USD
53% Upside
Highest
Price Target
72.45 USD
79% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MRUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MRUS Price
Merus NV

1M 1M
-10%
6M 6M
+93%
1Y 1Y
+90%
3Y 3Y
+83%
5Y 5Y
+140%
10Y 10Y
+303%
Annual Price Range
40.47
52w Low
18.46
52w High
51.82
Price Metrics
Average Annual Return 9.97%
Standard Deviation of Annual Returns 58.78%
Max Drawdown -49%
Shares Statistics
Market Capitalization 2.3B USD
Shares Outstanding 58 687 600
Percentage of Shares Shorted 5.91%

MRUS Return Decomposition
Main factors of price return

What is price return decomposition?

MRUS News

Other Videos

Company Profile

Merus NV Logo
Merus NV

Country

Netherlands

Industry

Biotechnology

Market Cap

2.3B USD

Dividend Yield

0%

Description

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Contact

UTRECHT
Utrecht
Yalelaan 62
+31850162500.0
https://www.merus.nl/

IPO

2016-05-19

Employees

121

Officers

CEO, President & Executive Director
Dr. Sven Ante Lundberg M.D.
Chief Financial Officer
Mr. Gregory D. Perry
EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Mr. Peter B. Silverman J.D.
Chief Business Officer, Executive VP & Head of Merus U.S.
Dr. Hui Liu Ph.D.
Chief Medical Officer & Senior VP
Dr. Andrew Joe M.D.
Co-Founder and Scientific Advisor
Dr. Hennie Hoogenboom
Show More
Chief Accounting Officer
Harry Shuman
CTO & Executive VP
Mr. Cornelis Adriaan de Kruif Ph.D.
Chief Scientific Officer & Senior VP
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
IR & Corporate Communications Officer
Kathleen Farren
Show Less

See Also

Discover More
What is the Intrinsic Value of one MRUS stock?

The intrinsic value of one MRUS stock under the Base Case scenario is 35.95 USD.

Is MRUS stock undervalued or overvalued?

Compared to the current market price of 40.47 USD, Merus NV is Overvalued by 11%.